Laurion Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Laurion Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-11,200	Closed	-$1.71M	–	1044
2021 Q1	$1.71M	Buy	11,200 +5,200	+87%	+$804K	0.01%	441
2020 Q4	$937K	Sell	6,000 -12,090	-67%	-$1.55M	0.01%	422
2020 Q3	$2.07M	Buy	+18,090	New	+$1.95M	0.02%	305
2019 Q3	–	Sell	-17,929	Closed	-$2.35M	–	1369
2019 Q2	$2.35M	Buy	+17,929	New	+$2.31M	0.02%	359
2017 Q4	–	Sell	-22,698	Closed	-$3.18M	–	1961
2017 Q3	$3.18M	Buy	+22,698	New	+$3.08M	0.01%	624
2017 Q2	–	Sell	-89,000	Closed	-$10.8M	–	1972
2017 Q1	$10.8M	Buy	+89,000	New	+$11.5M	0.08%	265
2016 Q2	–	Sell	-6,300	Closed	-$877K	–	1097
2016 Q1	$877K	Buy	+6,300	New	+$925K	0.01%	449
2015 Q3	–	Sell	-39,734	Closed	-$7.18M	–	981
2015 Q2	$7.18M	Buy	+39,734	New	+$6.86M	0.07%	242

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Laurion Capital Management's ALXN Position: Q2 2021 in Review

Laurion Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 11,200 shares — an estimated $1.71M sold.

Laurion Capital Management first reported a position in ALXN in Q2 2015 and held it in 8 quarters. The position peaked at $10.8M in Q1 2017. 707 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

Laurion Capital Management reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Laurion Capital Management sold 11,200 Alexion Pharmaceuticals shares in Q2 2021, an estimated $1.71M.
Laurion Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2015 and held it in 8 quarters.
Laurion Capital Management's Alexion Pharmaceuticals position peaked at $10.8M in Q1 2017.
707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Laurion Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.